RGS10 deficiency facilitates distant metastasis by inducing epithelial-mesenchymal transition in breast cancer.

A recent study highlighted in Women's Health Weekly suggests that a deficiency in the protein RGS10 may contribute to the development of distant metastasis in breast cancer. The study found that RGS10 protein levels were significantly lower in breast cancer tissues compared to normal breast tissues, and this deficiency was associated with a worse prognosis for patients. Silencing RGS10 in breast cancer cells led to enhanced epithelial-mesenchymal transition (EMT), migration, and invasion. The researchers suggest that RGS10 could serve as a tumor suppressor, prognostic biomarker, and potential therapeutic target for breast cancer. However, it's important to note that this study has not yet undergone peer review. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)